Risk of Melanoma Measured in Mutation Burden of Skin Cells
Mutation count could offer personal screening guidelines.
Mutation count could offer personal screening guidelines.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Imaging radiomics and blood markers could differentiate pseudoprogression.
More research is needed to define criteria for stopping therapy.
The FDA accepted a New Drug Application to support the combination of the MEK inhibitor, binimetinib, and the BRAF inhibitor, encorafenib, for treating patients with BRAF-mutated unresectable or metastatic melanoma.
Nicotinamide, a form of vitamin B3 (niacin), is a “promising and well-tolerated” chemopreventive agent for patients at high risk for developing skin cancer, according to the results of a recent review of the agent